RSS

Catalent

Catalent, provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has completed its tender offer for all outstanding shares of Juniper Pharmaceuticals. Read more

News

Catalent, global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has signed an agreement for the acquisition of Juniper Pharmaceuticals. Read more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

Do you encounter difficulties when swallowing tablets? Head of product development at Catalent Pharma Solutions, Ralph Gosden, reveals why the Zydis platform is still a game changer, and what is on the cards for the near future. Read more

Opinion

Global provider of advanced delivery technologies and development solutions, Catalent, and clinical-stage biotechnology company, Vaccinex, have signed an agreement for the development of an antibody drug conjugate (ADC) to be used against cancer Read more

News

As we reach the end of CPhI Worldwide, we have some more revelations and innovations that keep coming from the vast show floor here in Frankfurt Messe, enjoy and until next year tschüß! Read more

News

Here, Michael Merges, Catalent Biologics, and Brian Fahie, Biogen, discuss the growing need for partners who can provide niche technologies to accelerate development projects. Read more

, Opinion

Global provider of advanced delivery technologies and development solutions for drugs, Catalent, has reached an agreement to purchase Cook Pharmica, an integrated provider of drug substance and drug product manufacturing and related services. Read more

News

As Catalent further expands its softgel drug delivery capabilities with its acquisition of Accucaps, we speak with June Lin, global marketing director consumer health softgel, about the benefits these expanded capabilities will offer. Read more

Opinion

Catalent Pharma Solutions has revealed its agenda for the upcoming CPhI North America Conference and Exhibition Read more

News

Global supply partner for drugs, biologics and consumer health products, Catalent, has announced that it has completed the acquisition of pharmaceutical softgels developer and manufacturer, Accucaps. Read more

News

Chris Halling, director, global communications & marketing at Catalent writes about how drug design affects patient adherence. Read more

News

Provider of advanced delivery technologies and development solutions for drugs, Catalent Pharma Solutions has announced it will develop softgel technology for pharma company, Jupiter Orphan Therapeutics’ (JOT) formulation of resveratrol, JOTORL. Read more

News

Catalent Pharma Solutions, provider of advanced delivery technologies and development solutions for drugs has announced a collaboration with Path, a nonprofit organisation to advance a project funded by its Malaria Vaccine Initiative. Read more

News

Global CDMO Catalent has announced its enrollment in the Pharmaceutical Supply Chain Initiative (PSCI) Read more

News

Provider of advanced delivery technologies, Catalent Pharma Solutions, has announced it will provide fill-finish production services for the commercial supply of SB4, a biosimilar referencing Enbrel, which is used to treat five chronic diseases. Read more

News

Acquisition of west coast development and clinical manufacturing specialist will add formulation development capabilities and expands bioavailability enhancement solutions. Read more

News

Catalent Pharma Solutions has announced a commercial supply agreement with Palatin Technologies to globally launch Palatin’s bremelanotide pen injector product, which is used to treat female sexual dysfunction (FSD) Read more

News

Jennifer Mitcham, Catalent Biologics, offers insight into the new generation of antibody drug conjugates and the increasing importance biologics play in the fight against disease Read more

Opinion

Workshop will discuss accelerated preclinical drug development and readying molecules for phase I Read more

News